Abstract
Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy successfully treated by surgery in most patients. Locally advanced (la) and/or metastatic (m) cSCC require systemic treatments to either achieve complete remission or local control before subsequent surgery or radiotherapy. Recently, monoclonal antibodies against programmed cell death protein-1 (PD-1) have proven to be effective in several la/m cSCC treatment trials, with response rates up to 45 % and a one-year progression-free survival up to 55 %. Very recently, the use of anti-PD-1 as a neoadjuvant therapy was evaluated and resulted in a pathological response in almost two-thirds of tumors subsequently removed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
